International Society for Biological Therapy of Cancer
| Formation | 1984 |
|---|---|
| Type | Non-Profit Medical Society |
| Headquarters | Milwaukee, WI |
Official language | English |
Executive Director | Tara Withington |
President |
Howard L. Kaufman, MD, FACS Rutgers Cancer Institute of New Jersey |
Key people |
Vice President Lisa H. Butterfield, PhD University of Pittsburgh Secretary/Treasurer F. Stephen Hodi, Jr., MD Dana-Farber Cancer Institute Immediate Past President Francesco Marincola, MD Sidra Medical and Research Center |
| Website |
www |
The Society for Immunotherapy of Cancer (SITC), previously known as The International Society for Biological Therapy of Cancer (iSBTc) is a professional society of influential scientists, academicians, researchers, clinicians, government representatives, and industry leaders from around the world dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Currently, SITC has more than 1,300 members, representing 17 medical specialties, who are engaged in the research and treatment of at least a dozen types of cancer.
Through emphasis on high-caliber scientific meetings, dedication to education and outreach activities, focus on initiatives of major importance to the field, and commitment to collaborations with like-minded organizations and patient advocacy groups, SITC brings together all aspects of the cancer immunology and immunotherapy community in an effort to make cancer immunotherapy one of the four standards of care and the word “cure” a reality for cancer patients living with this disease.
The goals of SITC are directed towards the rapid dissemination of information in these areas to expedite the safe transfer of both basic and applied research to the clinical setting.
Core Values
Interaction/Integration - Facilitate the exchange of information and education among basic and translational researchers, practitioners, young investigators, societies and groups sharing the mission of SITC
Innovation - Challenge the thinking and seek the best research in the development of cancer immunotherapy
Translation - Facilitate the transfer of cancer immunology and immunotherapy research from the bench to the clinic and back
Leadership - Define what is new and important and effectively communicate it to all relevant stakeholders [1]
Activities
SITC holds multiple programs each year with the purpose of gathering leaders to discuss the latest developments in cancer immunotherapy and biological therapy, and to focus on and educate the clinical and translational aspects of biologic approaches to cancer treatment. [2]
Membership
SITC's membership consists of over 800 leaders and up-and-coming scientists in the field of biological therapy. This group includes academicians, government representatives, industry leaders, senior investigators, and students. SITC’s members represent 17 medical specialties and are engaged in research and treatment of at least a dozen types of cancer.[3]
Publications
The Journal for ImmunoTherapy of Cancer (JITC) is the official journal of the Society for Immunotherapy of Cancer (SITC). It is an open access, online journal created by the Society for the many stakeholders in the tumor immunology and cancer immunotherapy community. JITC is an outlet and targeted publication platform dedicated to advancing the science of tumor immunology and cancer immunotherapy. [4]
References
- ↑ "Core Values". About SITC. Retrieved 24 August 2016.
- ↑ "Meetings". SITC Meetings. Retrieved 18 March 2013.
- ↑ "General Society". General Society. Retrieved 18 March 2013.
- ↑ "JITC/SITC". About the Journal. Retrieved 18 March 2013.